Dear Visitor,
welcome to the newly arranged RAMIPRIL.org website!
From now on, the RAMIPRIL.org website will serve as a portal,
bringing together all
the information on RAMIPRIL.
The efficacy, safety and tolerability of RAMIPRIL has been
well documented. The RAMIPRIL
studies section offers you all studies on RAMIPRIL published
to date.
These publications are pre-structured for your convenience,
giving you instant access to the information you desire,
without leaving out any information given by the original
publication.
Learn about RAMIPRIL and its beneficial effects in hypertensive
diabetic patients on the
DREAM study website. The DREAM
study site furthermore deals with the effects of ROSIGLITAZONE
on insulin resistance, as one of the major pathogenetic
factors for diabetes mellitus.
The HOPE
(Heart Outcomes Prevention Evaluation) study was the
first large randomized and placebo-controlled clinical study
in patients with a high risk of progressive atherosclerotic
disease. Besides access to all HOPE-studies and sub-studies,
general information on cardiovascular diseases and diabetes
is provided, making it a reliable tool for learning and
teaching.
Haven't registered yet? Please Register
here
Disclaimer
This website may cite the use of this product in dosage,
indication, or any other manner different to local recommendations.
Before prescribing the product, the complete prescribing
information should be consulted. For the full prescribing
information applicable in your country, please contact your
local Sanofi Aventis representative.
